BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 52-Week Low at $4.44

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) reached a new 52-week low during trading on Friday . The company traded as low as $4.44 and last traded at $4.47, with a volume of 668065 shares traded. The stock had previously closed at $4.50.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $13.29.

BioCryst Pharmaceuticals Stock Performance

The firm's 50 day moving average is $5.24 and its 200-day moving average is $5.62. The stock has a market capitalization of $913.24 million, a price-to-earnings ratio of -3.75 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. lifted its position in BioCryst Pharmaceuticals by 7,385.4% in the second quarter. Point72 Asset Management L.P. now owns 4,004,700 shares of the biotechnology company's stock valued at $28,193,000 after buying an additional 3,951,200 shares during the last quarter. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 40.3% in the first quarter. Vanguard Group Inc. now owns 13,207,040 shares of the biotechnology company's stock valued at $214,746,000 after buying an additional 3,794,135 shares during the last quarter. State Street Corp lifted its position in BioCryst Pharmaceuticals by 47.5% in the second quarter. State Street Corp now owns 11,004,803 shares of the biotechnology company's stock valued at $116,431,000 after buying an additional 3,542,051 shares during the last quarter. Braidwell LP lifted its position in BioCryst Pharmaceuticals by 92.1% in the third quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock valued at $37,970,000 after buying an additional 2,571,100 shares during the last quarter. Finally, Norges Bank acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $13,278,000. Institutional investors and hedge funds own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.